Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

By A. Hauschild, J. Grob, L. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C. Blank, W. Miller, E. Kaempgen and 11 more. The Lancet, 2012

2,840 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/46a5949c622823cda3064bb3cee35b5acf273e38

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “51) Improved 4 [142, 143]”
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. (2014, neutral): “Increased creatine kinase 6 (3) 1 (<1) 0 0 23 (9) 27 (11) 17 (7) 9 (4)”
Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, methodology): “as well as stratification and analysis, are often based on the presence/absence of CNS disease.(6-20,73,74) Therefore, this additional level of granularity in the M category “maps” bet-”
Precision Oncology: The Road Ahead (2017, background): “Although targeting recurrent BRAF-mutation(s) by mutant-specific BRAF inhibitors demonstrated great clinical success [9, 17], understanding the complex feedback and cross-talk between key players of the altered RAS/RAF/MEK/ERK signaling axis became necessary for optimizing therapy.”
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy (2013, neutral): “With Ins(1,3,4,5)P 4 binding, R86 moved toward the 4-phosphate and K14 toward the 3- and 4-phosphates ( 25 ).”